The association between TP53 mutations and decreased antitumor immune responses has been uncovered in many cancers, such as head and neck squamous cell cancer (Lyu et al., 2019), gastric cancer (Jiang et al., 2018), and colon cancer (Li et al., 2020a). Here, TP53 is linked to cancer.